Neurofibromatosis: NF1, NF2-SWN & Targeted Care

1. Three Distinct Chromosomal Disorders — Never One Condition

Clinical Summary: Neurofibromatosis is an umbrella term for three genetically separate conditions that never turn into one another: Neurofibromatosis Type 1 (NF1, chromosome 17q11.2), NF2-related schwannomatosis (chromosome 22q12.2, formerly NF2), and non-NF2 schwannomatosis driven by SMARCB1 or LZTR1 variants on chromosome 22q11.2.

Families newly referred to genetics or neurology clinics frequently encounter outdated hospital pamphlets written around the 1987 National Institutes of Health consensus statement. Between 2021 and 2025, three major clinical advances reshaped routine care: the revised international diagnostic criteria separating NF1 from benign Legius syndrome (Legius et al., 2021), the unified schwannomatosis nomenclature (Plotkin et al., 2022), and the approval of two oral MEK1/2 inhibitors—selumetinib (Koselugo) and mirdametinib (Gomekli)—for inoperable plexiform neurofibromas.

When an existing plexiform neurofibroma requires urgent evaluation

In children or adults with NF1, persistent pain that wakes the patient from sleep, rapid focal enlargement, or a change from soft to firm/hard texture inside a plexiform neurofibroma requires prompt evaluation with 18F-FDG PET/CT (SUVmax ≥ 3.5) and targeted MRI to exclude malignant peripheral nerve sheath tumor (MPNST, 8%–13% lifetime NF1 risk).

Disorder (2022 Name)	Gene & Locus	Birth Incidence	Hallmark Features & First-Line Systemic Option
Neurofibromatosis Type 1 (NF1)	NF1 · 17q11.2 Neurofibromin	1 in 2,500–3,000	≥6 café-au-lait macules, skinfold freckling, cutaneous & plexiform neurofibromas, optic glioma (15%–20%). Oral selumetinib or mirdametinib.
NF2-Related Schwannomatosis	NF2 · 22q12.2 Merlin	1 in 25,000–33,000	Bilateral vestibular schwannomas (tinnitus, hearing/balance loss), meningiomas, spinal ependymomas. IV bevacizumab (anti-VEGF) & hearing preservation.
SMARCB1 / LZTR1 Schwannomatosis	22q11.2 SMARCB1, LZTR1	1 in 60,000–70,000	Multiple non-vestibular peripheral and spinal schwannomas presenting in adulthood with localized neuropathic pain. Nerve-sparing enucleation.

2. Interactive 2021 NF1 Diagnostic Criterion Checker

Select observed clinical findings below. In a person without an affected parent, two or more criteria establish clinical NF1; if a parent has confirmed NF1, one criterion is sufficient:

Six or more café-au-lait macules (CALMs)Over 5 mm longest diameter before puberty, or over 15 mm after puberty; total spot count never predicts disease severity. Axillary or inguinal freckling (Crowe sign)Skinfold freckling in non-sun-exposed regions, appearing typically between ages 3 and 5 years. Two or more neurofibromas of any type, OR one plexiform neurofibroma Optic pathway glioma (OPG)Tracked via annual quantitative visual acuity and OCT before age 8 rather than routine sedated MRI in asymptomatic children. Two or more iris Lisch nodules OR two or more OCT choroidal abnormalities Distinctive osseous lesionSphenoid wing dysplasia, anterolateral bowing of the tibia, or long-bone pseudarthrosis. Heterozygous pathogenic NF1 variantVariant allele fraction near 50% in unaffected tissue such as blood leukocytes.

2 pigmentary criteria selected: Meets numeric count, but isolated café-au-lait macules plus skinfold freckling without tumors also occurs in benign Legius syndrome (SPRED1). Paired NF1/SPRED1 sequencing is recommended.

3. Nerve-Sheath Pathology & 2025–2026 Targeted Therapy

Understanding how neurofibromas and schwannomas interact with peripheral nerve axons explains why NF1 plexiform tumors respond to oral MEK1/2 blockade while encapsulated schwannomas are managed through microsurgical cleavage planes or anti-VEGF therapy:

Figure 1. Plexiform neurofibromas (B) infiltrate between functional axons without a capsule, making complete resection hazardous and establishing oral MEK1/2 inhibition (selumetinib or mirdametinib) as standard systemic care. Schwannomas (C) remain encapsulated.

Frequently Asked Clinical Questions

Can Neurofibromatosis Type 1 turn into NF2 later in life?

No. NF1 is caused by variants in the NF1 gene on chromosome 17q11.2, whereas NF2-related schwannomatosis is caused by variants in the NF2 gene on chromosome 22q12.2. One condition never transforms into the other.

Does having more cafe-au-lait spots mean a child will have more severe NF1?

No. Whether a child has 6 cafe-au-lait macules or 20 macules has zero correlation with tumor burden, learning differences, or long-term severity.

What are the two FDA-approved oral medications for NF1 plexiform neurofibromas?

Selumetinib (Koselugo), taken continuously across a 28-day cycle, and mirdametinib (Gomekli, approved February 2025 for adults and children aged 2 years and older), taken 21 days on and 7 days off with a water-dispersible pediatric tablet option.

Key Consensus Guidelines & Primary Sources

Legius E, Messiaen L, Wolkenstein P, et al. Revised diagnostic criteria for neurofibromatosis type 1 and Legius syndrome: an international consensus recommendation. Genetics in Medicine. 2021;23(8):1506–1513. PubMed 34012067.
Plotkin SR, Messiaen L, Legius E, et al. Updated diagnostic criteria and nomenclature for neurofibromatosis type 2 and schwannomatosis: an international consensus recommendation. Genetics in Medicine. 2022;24(9):1967–1977. PubMed 35674741.
Gross AM, Wolters PL, Dombi E, et al. Selumetinib in children with inoperable plexiform neurofibromas (SPRINT Phase II). New England Journal of Medicine. 2020;382(15):1430–1442. PubMed 32187457.
Moertel CL, Hirbe AC, Shuhaiber HH, et al. ReNeu: A pivotal phase IIb trial of mirdametinib in adults and children with symptomatic neurofibromatosis type 1-associated plexiform neurofibroma. Journal of Clinical Oncology. 2025;43(7):758–769. PubMed 39514828.
Miller DT, Freedenberg D, Schorry E, et al. Health supervision for children with neurofibromatosis type 1 (American Academy of Pediatrics). Pediatrics. 2019;143(5):e20190660. PubMed 30988031.